Post-Conference Focus Morning - Friday, March 25

Continuous Processing in Applications in Cell & Gene Therapy, Vaccines & Non-Traditional Modalities

9:00 AM

The Future of mRNA Production: A Case Study in Continuous Manufacturing via QBD, PAT & Digital Twins

  • A future looking methodology developed to implement Quality by Design (QbD) in continuous manufacturing for mRNA
  • Potential pharmaceutical application and how this may impact development and manufacturing timelines & capacity
  • Next steps to further scale this technology
AnyConv.com__Mark Geng Moderna

Mark Geng
Principal Scientist
Moderna

Lei Zhou

Lei Zho
Sr. Research Associate, Process Development
Moderna

9:30 AM

FireSide Chat: Continuous Processing for Oligonucleotides & Exosomes

  • Exosome manufacturing is a relatively new scientific field, with production is limited by sample purity and scalability, how are Exopharm overcoming these challenges through continuous processing?
  • Can continuous processing be applied to allow the large-scale processing needed for commercialized products in oligonucleotides and Exosomes?
  • What are the bottleneck to advancing continuous processing in these applications?
AnyConv.com__Mark Geng Moderna

Mark Geng
Principal Scientist
Moderna

Martin Johnson Eli Lilly

Martin Johnson
Senior Engineering Advisor, Process Design & Development
Eli Lilly and Company

Mike West Exopharm

Michael West
CTO
Exopharm

10:00 AM

Refreshment Break

10:30 AM Impinging Jet in Continuous Processing – A Bridge to Continuous Vaccine Production?

  • Scale up of impinging jet in continuous processing to pilot scale
  • Use of technology in vaccines
  • Future work
AnyConv.com__David Voigtlaender Evonik

David Voigtlaender
Director – Innovation Management
Evonik

11:10 AM

Panel Discussion: Continuous Processing Potential Outside of Traditional Small Molecule & Monoclonal Antibody Applications

  • What technologies are available for cell, gene and vaccine continuous manufacturing?
  • How close are these technologies to commercialization? - How easy are commercially available technologies able to be adapted to process needs?
  • What are the drivers for exploring CM for modalities outside of the traditional small molecules & monoclonal antibodies?
Simon howdon CPI

Simon Hawdon
Principal Scientist
CPI Biologics

AnyConv.com__David Voigtlaender Evonik

David Voigtlaender
Director – Innovation Management
Evonik

Mike West Exopharm

Michael McCaman
Managing Director
BPTG, BDO

12:00 PM

End of Focus Day